ストックスクリーナーアプリを入手
34.02
10.69%
-4.07
アフターアワーズ：
34.11
0.09
+0.26%
Qiagen Nv (QGEN) 最新ニュース
QIAGEN NV : Jefferies keeps its Buy rating - marketscreener.com
Qiagen NV (QGEN) PT Lowered to $38 at Barclays - StreetInsider
Qiagen (NYSE:QGEN) Sees Strong Trading VolumeShould You Buy? - MarketBeat
German Shares Slip; Qiagen Tumbles on Outlook Downgrade - marketscreener.com
Qiagen N.V. 2026 Q1ResultsEarnings Call Presentation (NYSE:QGEN) 2026-04-28 - Seeking Alpha
Qiagen: Weak Q1 and guidance cut unsettle the market - marketscreener.com
Barclays Maintains Qiagen NV(QGEN.US) With Hold Rating, Maintains Target Price $44 - Moomoo
Deutsche Bank Maintains Qiagen NV(QGEN.US) With Buy Rating - Moomoo
Qiagen Sets Date for Publication of 2025 Annual Financial Report - TipRanks
QIAGEN NV : Deutsche Bank remains its Buy rating - marketscreener.com
QIAGEN NV : Jefferies gives a Buy rating - marketscreener.com
QIAGEN NV : Barclays remains Neutral - marketscreener.com
Qiagen Trims Guidance for FY26, Warns of Lower Net Sales in Q2 - marketscreener.com
Qiagen cuts 2026 outlook on lower immigration testing demand - Investing.com UK
QIAGEN lowers 2026 outlook as QuantiFERON immigration testing drops - StreetInsider
QIAGEN (QGEN) Revises 2026 Sales Growth Outlook - GuruFocus
Qiagen (QGEN) Shares Decline Following Earnings Guidance Revisio - GuruFocus
Qiagen (NYSE:QGEN) Updates FY 2026 Earnings Guidance - MarketBeat
Qiagen (NYSE:QGEN) Updates Q2 2026 Earnings Guidance - MarketBeat
Qiagen (NYSE:QGEN) Releases Q1 2026 Earnings Guidance - MarketBeat
QIAGEN NV cuts FY outlook despite in-line prelim Q1 EPS - MSN
Qiagen cuts 2026 outlook on lower immigration testing demand By Investing.com - Investing.com Nigeria
QIAGEN N.V.: QIAGEN announces preliminary Q1 2026 results that achieved adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook by reducing expected net sales growth and adj. EPS - marketscreener.com
QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook - Business Wire
Qiagen gains on report it's weighing options amid takeover interest - MSN
Qiagen Sees Unusually High Options Volume (NYSE:QGEN) - MarketBeat
QIAGEN expands portfolio for MRD testing in oncology with two partnerships - MSN
Qiagen N.V. (QGEN) Stock Analysis: Exploring A 40% Potential Upside For Investors - DirectorsTalk Interviews
RT-PCR Market key players 2025-2031 : Abbott, Qiagen, GE - openPR.com
Agilent, Danaher could be potential buyers of Qiagenanalyst - MSN
Tracer Biotechnologies and QIAGEN to advance blood-based MRD testing for solid tumors - MSN
Is Qiagen’s (QGEN) New Infection and Oncology Tools Quietly Rewiring Its Diagnostics Moat? - simplywall.st
Q3 2025 Qiagen NV Earnings Call Transcript - GuruFocus
Brown AdvisoryWMC Strategic European Equity Fund's Qiagen NV(XTER:QIA) Holding History - GuruFocus
QIAGEN NV Hits New 52-Week Low at USD 37.44 Amid Declining Performance - Markets Mojo
Qiagen NV (QGEN) Shares Fall 5.0% -- What GF Score of 79 Tells I - GuruFocus
Qiagen (NYSE:QGEN) Reaches New 52-Week LowHere's Why - MarketBeat
Qiagen NV (QGEN) Stock Price, Trades & News - GuruFocus
Universal Beteiligungs und Servicegesellschaft mbH Sells 559,616 Shares of Qiagen N.V. $QGEN - MarketBeat
Qiagen N.V. stock (NL0012169213): Is its molecular diagnostics edge strong enough to unlock new upsi - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): Is its genomics leadership strong enough to unlock new upside? - AD HOC NEWS
Barclays Downgrades Qiagen NV(QGEN.US) to Hold Rating, Cuts Target Price to $44 - 富途牛牛
Qiagen N.V. stock (NL0012169213): Is its diagnostics dominance strong enough to unlock new upside? - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): Why does its molecular diagnostics edge matter more for U.S. inves - AD HOC NEWS
Qiagen N.V. (QGEN) Stock Analysis: Unlocking a 30% Upside Potential in the Diagnostics & Research Sector - DirectorsTalk Interviews
Qiagen N.V. stock (NL0012169213): Why does its genomics leadership matter more for U.S. investors no - AD HOC NEWS
Assessing Qiagen (NYSE:QGEN) Valuation After New Diagnostics Launches And Oncology Workflow Expansion - Sahm
Qiagen N.V. stock (NL0012169213): Is its molecular diagnostics leadership strong enough for growth i - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): Is its molecular diagnostics edge strong enough for steady growth? - AD HOC NEWS
Is Qiagen (QGEN) stock considered a safe play (+0.68%) 2026-04-18ATR Levels - Cổng thông tin điện tử Tỉnh Sơn La
Qiagen (NYSE:QGEN) Valuation Check After Recent Share Price Swings - Yahoo Finance
Qiagen N.V. stock (NL0012169213): Is its molecular diagnostics leadership strong enough to unlock ne - AD HOC NEWS
Qiagen NV at Citi Global Healthcare Conference Transcript - GuruFocus
Qiagen Expands Diagnostic Portfolio Amid Renewed Takeover Interest - HarianBasis.co
QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026 - BioSpace
QIAGEN Showcases AI-Driven Oncology Innovations at AACR 2026 - World Business Outlook
QIAGEN N.V.: QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026 - FinanzNachrichten.de
Genotyping Market Major PlayersQIAGEN NV, Merck KGaA, Eurofins Genomics, BioTek Instruments Inc - openPR.com
How QIAGEN’s (QGEN) Diagnostics Expansion Strengthens Its Takeover Appeal - Insider Monkey
1.47%
0.31%
大文字化:
|
ボリューム (24 時間):